What Four Days at SRS 2026 Taught Me About Where Surgical Robotics Is Actually Going
- Jul 25
- 4 min read
Updated: Jul 25
If you know me, then you know surgical robotics is my sweet spot, so there was no way I was missing SRS2026!
There's a moment at every conference where the story tells on itself.
For me, that was at the pre-conference investor sessions on Wednesday.
Dr. Vip Patel showed a telesurgery case performed more than 1,500 kilometers away with just 51 milliseconds of latency. This is great from a conceptual or humanitarian perspective, but what about real life? What about:
Licensure?
Credentialing?
Liability?
Reimbursement?
Cybersecurity?
Staff Training?
Contingency planning?
Patient ownership?
The human element?
The entire patient journey?
That gap, between what the technology can do and what the healthcare system is actually prepared to support, was the real theme of the meeting.
Nobody put it on a slide, but it was discussed heavily.
The Market Is Maturing. That's a Polite Way of Saying It's About to Cull the Herd.
Thirty-six multiport robotic platforms are now competing for the soft tissue market.
Read that again. Price doesn't create a moat strong enough to withhold the competitors from storming your castle.
The forecasts show robotic penetration growing from roughly one-third of procedures today to nearly half within five years.
The forecasts don't say all thirty-six companies survive long enough to enjoy it.
Consolidation has already begun. Follow where the strategics are investing to know who has the best chances of surviving.
The ASC Gold Rush Has a Math Problem
Johnson & Johnson's announcement of a robotic platform with a footprint roughly 30 to 50% smaller landed at exactly the right time.
Every panel that morning was discussing migration into ambulatory surgery centers.
Smaller robots. Smaller rooms. Clear strategy.
But strategy doesn't replace economics.
A fair share of ASCs are physician-owned. When the person performing the procedure is also signing the purchase order, pricing stops being one slide in the deck and becomes the entire conversation.
Everyone wants to sell robots into ASCs.
Far fewer companies have built the financial model their customer is already calculating.
Telesurgery: Bullish Locally. Bearish Across Borders.
I walked into SRS optimistic about telesurgery.
I left even more convinced the technology works.
Latency below roughly 150 milliseconds is essentially imperceptible. The best demonstrations are operating at nearly one-third of that. With fiber optics running through essentially every hospital system in the US, the scalability is very real.
We've now seen remote procedures performed from Orlando to Angola under an FDA IDE. More than fifty countries have approved some form of telesurgery.
Technology is no longer the bottleneck.
Everything downstream is.
These are commercialization problems.
The most valuable telesurgery conversation I had all week wasn't with engineers. It was with hospital administrators.
Their comparison wasn't autonomous driving. It was the tele-ICU.
Deploy telesurgery inside a single integrated delivery network. Keep licensure internal. Credential internally. Build around existing reimbursement structures. Use it to extend specialists into rural hospitals that struggle to recruit and retain talent.
The economics become compelling almost immediately.
Here's my five-year prediction.
Telesurgery succeeds inside large health systems, connecting urban specialists to rural hospitals.
Cross-border telesurgery at scale remains more demonstration than deployment.
I'm bullish on the first.
I'm still bearish on the second.
Humanoids: Brilliant Minds Looking for Functional Bodies
Three humanoid robots worked the exhibit floor.
China is pulling ahead in hardware development, manufacturing scale, and capital deployment. The projections being discussed, a trillion-dollar market and billions of humanoids over the coming decades, were delivered with remarkable confidence.
The most honest comment of the week came from a single presenter.
"A humanoid with AI is the smartest kid on the block who still hasn't learned to walk."
That line stuck with me.
The intelligence is advancing rapidly.
The physical capabilities aren't.
There is no mature experience library.
No large-scale procedural dataset.
No proven safety framework.
And hospitals themselves weren't designed for humanoid workflows. except for the creepy ones roaming the hospital basement hallways.
The software is accelerating faster than the body.
This space is absolutely worth watching.
Just don't confuse momentum with readiness.
Neuro Was the Most Interesting Room at the Conference
Despite Neuro and Spine not having much of a presence in the exhibit hall, Saturday morning featured eleven neurovascular and neurosurgical robotics companies presenting back-to-back on some exciting new technologies.
Most were European or Israeli.
Nearly all were pursuing the same destination:
Remote thrombectomy. It makes perfect sense.
Stroke is one of the few clinical areas where every minute lost translates directly into measurable neurological damage. The milestones are impressive.
Fully remote human neuro-intervention has happened. Transatlantic remote intervention has happened. First-in-human robotic aneurysm treatment has happened.
Strategic investors are paying attention too, with one major thrombectomy company leading an $18 million Series A investment into a magnetic navigation startup.
But watching all eleven presentations revealed something more interesting.
The engineering is beginning to converge.
Commercial execution isn't.
Several companies demonstrated world-class technology paired with U.S. commercialization strategies that felt unfinished.
In markets this competitive, engineering earns you a seat at the table.
Commercialization determines who stays there.
The Bottom Line
Whether the discussion centered on orthopedics, telesurgery, neurovascular robotics, investors, or AI, every conversation eventually landed on the same three questions.
Who pays?
Who's liable?
Who implements it?
A decade ago, surgical robotics were fundamentally an engineering challenge.
SRS 2026 made something clear. Today, it's a commercialization challenge.
The companies that recognize that first won't be presenting TAM slides next year. They'll be presenting U.S. launch results.
See you in Rome, SRS 2027!
Comments